CPN | Community input is valued but every trial design is unique

Community input is valued but every trial design is unique

In this video, a patient advocate in biotechnology discusses the valued input of the patient community in clinical trials, explaining that every trial design is unique and the process varies company to company, phase to phase, and between different types of investigational products. She also touches on the formality of many of the steps required in gene therapy trials.